

**ZHI DONG JIANG**

**Nov. 20, 2006**

**Business Address:**

The University of Texas Health Science Center at Houston  
Center for Infectious Diseases  
P.O. Box 20186, Houston, TX 77225  
Voice Mail: (713) 500-9371  
Fax: (713) 500-9364

**Education:**

1995 – 1998 The University of Texas School of Public  
Health Houston TX  
Doctor of Public Health

1992 – 1994 The University of Texas School of Public  
Health Houston TX  
Master of Public Health

1978 - 1983, Beijing Medical University, Beijing, China  
Doctor of Medicine

**Awards:**

1998 Guy and Alissa McDaniels Memorial Scholarship  
The University of Texas School of Public Health

1982 Dean's Excellent Students List  
Beijing Medical University

**Professional:**

1999 – present The University of Texas School of Public  
Health Houston, TX  
Assistant Professor in the Center for Infectious Disease.

1996 –1998 The University of Texas School of Public  
Health Houston TX  
Senior research assistant in the Center for Infectious  
Disease. Supervision of laboratory and epidemiologic  
studies in the University of Texas Enteric Infectious  
Diseases Unit

1995 – 1996 Baylor College of Medicine Houston TX

Senior project coordinator in the Department of Surgery. Research on multicenter clinical trial for cholesterol lowering therapy and follow-up program. Work included developing a customized database for the Department, performing descriptive statistical evaluations on the database, preparing the report and implementation of an analysis plan to answer research questions

1994 – 1995 The University of Texas

M.D. Anderson Cancer Center, Houston TX

Research data manager in the Department of Surgical Oncology. Work included synthesizing information gathered from various sources, developing customized databases for the Department and maintaining computer associated top secret security system software

1988 – 1994 The University of Texas Medical School

Houston TX

Research fellow in the Department of Internal Medicine. Research on large-scale molecular epidemiologic studies of intestinal sIgA immune responses against enteropathogens in patients with travelers' diarrhea and African HIV positive patients with diarrhea. Methods included tissue culture, FACS scan and PCR

1983 – 1988 Capital Pediatric Institute

Beijing China

Pediatrician in the Department of Infectious Diseases. Over these five years advanced from pediatric resident to chief resident

**Scientific Interests:** In the past 15 years I have devoted my efforts to the preservation of public health, specifically in the area of infectious diseases, through training and working in the Disease Control Module and Center for Infectious Diseases of The University of Texas School of Public Health. After my graduation from Beijing Medical University, I participated in a UNICEF project evaluating nutrition factors as the cause of children's diarrhea in China. Because the causes of epidemic diseases in developing countries are complex and because an understanding of public health is fundamental to tackling these diseases, I came to the United States to pursue my interest in laboratory research. Since infectious disease diagnosis and prevention have always been associated with the laboratory and public health, I became a student of the School of Public Health majoring in Disease Control. My long-term career goals are to focus on epidemiologic medical problems in developing countries, worldwide. I also intend to

participate in projects that will contribute to the prevention and eradication of serious epidemic diseases in developing countries. Furthermore, I would like to educate and share my knowledge with public health professionals in developing countries to help them become world class health professionals.

**Publications:**

1. **Jiang ZD**, Xie BC. Prediction from systolic time intervals of the size of the defect and hemodynamic changes in children with ventricular septal defect. Chinese Medical Journal 1985;65:603-606
2. **Jiang ZD**, Fang HS. Observation of immune response against *Shigella* among children with chronic diarrhea. Chinese Journal Clinical Epidemiology 1987;15:684-688
3. **Jiang ZD**, Nelson AC, Mathewson JJ, Ericsson CD, DuPont HL. Intestinal secretory immune response to infection with *Aeromonas* species and *Plesiomonas shigelloides* among students from the United States in Mexico. Journal of Infectious Diseases 1991;164:979-982
4. Mathewson JJ, **Jiang ZD**, DuPont HL, Chintu C, Luo N, Zumla A. Intestinal secretory IgA immune response against human immunodeficiency virus among infected patients with acute and chronic diarrhea. Journal of Infectious Diseases 1994;169:614-617
5. **Jiang ZD**, Smith MA, Kelsey K, DuPont HL, Mathewson JJ. Effects of storage time and temperature on fecal leukocytes and occult blood in the evaluation of travelers' diarrhea. Journal of Travel Medicine 1994;1:184-186
6. Mathewson JJ, **Jiang ZD**, Zumla A, Chintu C, Luo N, Calamari SR, Genta RM, Atephen A, Schwartz P, DuPont HL. HEp-2 cell adherent *E. coli* in patients with human immunodeficiency virus associated diarrhea. Journal of Infectious Diseases 1995;171:1636-1639
7. Plestis KA, **Jiang ZD**, Appel H, Howell JF. Treatment of recurrent carotid disease: Report on a 12-year experience. Vascular Surgery 1997;31:693-701
8. Plestis KA, Loubser P, Mizrahi EM, Kantis G, **Jiang ZD**, Howell JF. Continuous electroencephalographic monitoring and selective shunting reduces neurologic morbidity rates in carotid endarterectomy. Journal of Vascular Surgery 1997;25:620-628
9. Mathewson JJ, Salameh BM, DuPont HL, **Jiang ZD**, Nelson AC, Arduino R, Smith A, Masozera N. HEp-2 cell adherent *Escherichia coli* and intestinal secretory immune response to human immunodeficiency virus (HIV) in outpatients with HIV-associated diarrhea. Clinical & Diagnostic Laboratory Immunology 1998;5:87-90

10. DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, **Jiang ZD**, Mosavi A, Cabada FJ. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. *Digestion* 1998;59:708-714
11. Plestis KA, Ke S, **Jiang ZD**, Howell JF. Combined carotid endarterectomy and coronary artery bypass: immediate and long-term results. *Annals of Vascular Surgery* 1999;13:84-92
12. Caeiro JP, Mathewson JJ, Smith MA, **Jiang ZD**, Kaplan MA, DuPont HL. Etiology of outpatient pediatric nondysenteric diarrhea: a multicenter study in the United States. *Pediatric Infectious Disease Journal* 1999;18:94-7
13. Glandt M, Adachi JA, Mathewson JJ, **Jiang ZD**, Cesare D, Ashley D, Ericsson CD, DuPont HL. Enteroaggregative *Escherichia coli* as a cause of travelers' diarrhea: Clinical response to ciprofloxacin. *Clinical Infectious Disease* 1999;29:335-8
14. Caeiro JP, Estrada-Garcia M, **Jiang ZD**, Mathewson JJ, Adachi JA, Steffen R, DuPont HL. Improved detection of enterotoxigenic *Escherichia coli* among patients with travelers' diarrhea by using polymerase chain reaction technique. *Journal of Infectious Diseases* 1999;180:2053-5
15. **Jiang ZD**, Mathewson JJ, Ericsson CD, Svennerholm AM, Pulido C, DuPont HL. Characterization of enterotoxigenic *Escherichia coli* (ETEC) strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992 through 1997. *Journal of Infectious Diseases* 2000;181:779-782
16. Paredes P, Campbell-Forrester S, Mathewson JJ, Ashley D, Thompson S, Steffen R, **Jiang ZD**, Svennerholm AM, DuPont HL. Etiology of travelers' diarrhea on a Caribbean island. *Journal of Travel Medicine* 2000;7:15-18
17. Sutjita M, Bouckenoghe AR, Adachi JA, **Jiang ZD**, Mathewson JJ, Ericsson CD, DuPont HL. Intestinal secretory immunoglobulin A response to enteroaggregative *Escherichia coli* in travelers with diarrhea. *Clinical Diagnostic Laboratory Immunology* 2000;7:501-503
18. **Jiang ZD**, Ke S, Riopel LM, Palazzini E, DuPont HL. Rifaximin therapy of travelers' diarrhea: In vitro activity and fecal concentration after oral administration. *Antimicrobial Agents and Chemotherapy* 2000;44:2205-2206
19. Bouckenoghe AR, DuPont HL, **Jiang ZD**, Adachi J, Mathewson JJ, Verenkar MP, Rodrigues S, Steffen R. Markers of enteric inflammation in enteroaggregative *Escherichia coli* diarrhea in travelers. *American Journal Tropical Medicine Hygiene* 2000;62:711-713
20. Adachi JA, **Jiang ZD**, Cox MA, Wood L, DuPont HL, Mathewson JJ. Serum antibody response induced in mice after oral administration of three different

antigens of enterotoxigenic *Escherichia coli* in enteric coated microparticles. *Journal of Travel Medicine* 2000;7:304-308

21. Gomi H, **Jiang ZD**, Adachi JA, Ashley D, Lowe B, Verenkar MP, Steffen R, DuPont HL. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing travelers' diarrhea in four geographic regions. *Antimicrobial Agents & Chemotherapy* 2001;45:212-216
22. DuPont HL, **Jiang ZD**, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of travelers' diarrhea: A randomized, double-blind clinical trial. *Clinical Infectious Diseases* 2001;33:1807-1815
23. Adachi JA, **Jiang ZD**, Mathewson JJ, Verenkar MP, Thompson S, Martinez-Sandoval F, Steffen R, Ericsson CD, DuPont HL. Enteroaggregative *Escherichia coli* as a major etiologic agent in travelers' diarrhea in 3 regions of the world. *Clinical Infectious Diseases* 2001;32:1706-1709
24. Cardin VA, Grimes RM, **Jiang ZD**, Pomeroy N, Harrell L, Cano P. Low-income minority women at risk for cervical cancer: a process to improve adherence to follow-up recommendations. *Public Health Reports*. 2001;116:608-616
25. Huang DB, **Jiang ZD**, Ericsson CD, Adachi J, Dupont HL. Emergence of trimethoprim-resistant *Escherichia coli* in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. *Scandinavian Journal of Infectious Diseases*. 2001;33:812-814
26. **Jiang ZD**, Lowe B, Verenkar MP, Ashley D, Steffen R, Tornieporth N, von Sonnenburg F, Svennerholm AM, Waiyaki P, DuPont HL. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa) and Jamaica (Montego Bay). *Journal of Infectious Diseases* 2002;185:497-502
27. Greenberg DE, **Jiang ZD**, Steffen R, Verenker MP, DuPont HL. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative *Escherichia coli* pathogenicity. *Journal of Infectious Diseases*. 2002;185:944-949
28. Estrada-Garcia MT, **Jiang ZD**, Adachi J, Mathewson JJ, DuPont HL. Intestinal immunoglobulin a response to naturally acquired enterotoxigenic *Escherichia coli* in US travelers to an endemic area of Mexico. *Journal of Travel Medicine*. 2002;9:247-250
29. **Jiang ZD**, Greenberg D, Nataro JP, Steffen R, DuPont HL. Rate of occurrence and pathogenic effect of enteroaggregative *Escherichia coli* virulence factors in international travelers. *Journal of Clinical Microbiology*. 2002;40:4185-4190

30. Miqdady MS. **Jiang ZD**. Nataro JP. DuPont HL. Detection of enteroaggregative *Escherichia coli* with formalin-preserved HEp-2 cells. *Journal of Clinical Microbiology* 2002;40:3066-3067
31. Bouckenooghe AR. **Jiang ZD**. De La Cabada FJ. Ericsson CD. DuPont HL. Enterotoxigenic *Escherichia coli* as cause of diarrhea among Mexican adults and US travelers in Mexico. *Journal of Travel Medicine*. 2002;9:137-140
32. Adachi JA. Mathewson JJ. **Jiang ZD**. Ericsson CD. DuPont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. *Annals of Internal Medicine*. 2002;136:884-887
33. Adachi JA. Ericsson CD. **Jiang ZD**. DuPont MW. Pallegar SR. DuPont HL. Natural history of enteroaggregative and enterotoxigenic *Escherichia coli* infection among US travelers to Guadalajara, Mexico. *Journal of Infectious Diseases*. 2002;185:1681-1683
34. **Jiang ZD**. Okhuysen PC. Guo DC. He R. King TM. DuPont HL. Milewicz DM. Genetic susceptibility to enteroaggregative *Escherichia coli* diarrhea: polymorphism in the interleukin-8 promotor region. *Journal of Infectious Diseases*. 2003;188:506-511
35. Steffen R. Sack DA. Riopel L. **Jiang ZD**. Sturchler M. Ericsson CD. Lowe B. Waiyaki P. White M. DuPont HL. Therapy of travelers' diarrhea with rifaximin on various continents. *American Journal of Gastroenterology*. 2003;98:1073-1078
36. Adachi JA. Ericsson CD. **Jiang ZD**. DuPont MW. Martinez-Sandoval F. Knirsch C. DuPont HL. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. *Clinical Infectious Diseases* 2003;37:1165-1171
37. DuPont HL, **Jiang ZD**. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. *Clin Microbiol Infect*. 2004 Nov;10(11):1009-11
38. Okhuysen PC, **Jiang ZD**, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. *Am J Gastroenterol*. 2004 Sep;99(9):1774-8
39. Huang DB, DuPont HL, **Jiang ZD**, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic *Escherichia coli*. *Clin Diagn Lab Immunol*. 2004 May;11(3):548-51

40. Huang DB, Okhuysen PC, **Jiang ZD**, DuPont HL. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol. 2004 Feb;99(2):383-9. Review.
41. Infante RM, Ericsson CD, **Jiang ZD**, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol. 2004 Feb;2(2):135-8.
42. Huang DB, Sanchez AP, Triana E, **Jiang ZD**, DuPont HL, Ericsson CD. United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. J Travel Med. 2004 May-Jun;11(3):143-5.
43. **Jiang ZD**, Okhuysen PC, Zaidi M, Niyogi SK, Ruiz-Palacios G, Talukder KA, DuPont HL. Susceptibility of Multi-drug Resistant Bacterial Enteropathogens of Global Origin to New Antimicrobial Agents. Antimicrobial Agents and Chemotherapy (in press)
44. DuPont HL, **Jiang ZD**, Okhuysen PC, Ericsson CD, de la Cabada JF, Ke S, DuPont MW, Martinez-Sandoval F. Rifaximin Prevention of Travelers' Diarrhea in Mexico. A Randomized Placebo Controlled Trial. Annals of Internal Medicine (in press)
45. [Mohamed JA](#), [Huang DB](#), [Jiang ZD](#), [Dupont HL](#), [Nataro JP](#), [Belkind-Gerson J](#), [Okhuysen PC](#). Association of Putative Enteroaggregative Escherichia coli Virulence Genes and Biofilm Production in Isolates from Travelers to Developing Countries. J Clin Microbiol. 2006 Nov
46. [Taylor DN](#), [Bourgeois AL](#), [Ericsson CD](#), [Steffen R](#), [Jiang ZD](#), [Halpern J](#), [Haake R](#), [Dupont HL](#). A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.
47. [Garey KW](#), [Graham G](#), [Gerard L](#), [Dao T](#), [Jiang ZD](#), [Price M](#), [Dupont HL](#). Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun;40(6):1030-4. Epub 2006 May 9.
48. [Ko G](#), [Jiang ZD](#), [Okhuysen PC](#), [DuPont HL](#). Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol. 2006 Jun;78(6):825-8.
49. [Jiang ZD](#), [DuPont HL](#), [Garey K](#), [Price M](#), [Graham G](#), [Okhuysen P](#), [Dao-Tran T](#), [LaRocco M](#). A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May;101(5):1112-6
50. [Ko G](#), [Garcia C](#), [Jiang ZD](#), [Okhuysen PC](#), [Belkind-Gerson J](#), [Glass RI](#), [DuPont HL](#). Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol. 2005 Dec;43(12):6126-9.
51. [DuPont HL](#), [Jiang ZD](#), [Okhuysen PC](#), [Ericsson CD](#), [de la Cabada FJ](#), [Ke S](#), [DuPont MW](#), [Martinez-Sandoval F](#). Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis. 2005 Dec 1;41 Suppl 8:S571-6.
52. [Jiang ZD](#), [DuPont HL](#). Rifaximin: in vitro and in vivo antibacterial activity--a review. Chemotherapy. 2005;51 Suppl 1:67-72. Review.

53. [Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL](#). Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. *Am J Gastroenterol*. 2004 Sep;99(9):1774-8.
54. [Huang DB, Jiang ZD, Dupont HL](#). Association of virulence factor-positive and -negative enteroaggregative *Escherichia coli* and occurrence of clinical illness in travelers from the United States to Mexico. *Am J Trop Med Hyg*. 2003 Nov;69(5):506-8.
55. [Estrada-Garcia MT, Jiang ZD, Adachi J, Mathewson JJ, DuPont HL](#). Intestinal immunoglobulin a response to naturally acquired enterotoxigenic *Escherichia coli* in US travelers to an endemic area of Mexico. *J Travel Med*. 2002 Sep-Oct;9(5):247-50.

## Investigator

### LAB:04-01

**9/1/2005 – 2/28/2006**

Salix Pharmaceuticals, Inc. \$38,542  
 “Mechanism of Action of Rifaximin Antimicrobial Effects and Drug-Induced Alteration of Microbial Virulence of Enterotoxigenic (ETEC) and Enteroaggregative (EAEC) *Escherichia coli*”

Investigator

Lab Study: 7/1/2005 – 10/15/2005  
 Salix Pharmaceuticals, Inc. \$20,000  
 “In Vitro Antibacterial Activity of Rifaximin Against Bacterial Enteropathogen Strains That Cause Pediatric Diarrhea in Cincinnati Children’s Hospital Medical Center”

This study was an in vitro determination of the minimum inhibitory concentrations (MICs) of rifaximin against bacterial strains known to cause pediatric diseases.

Co-Investigator

(Okhuysen, P.C.) 10/03 – 02/07  
 Souce: NIH R01 AI54948-01 \$1,852,576  
 Gene Polymorphisms that Predispose to Infectious Diarrhea

Overall goal: The primary objectives of this study are to identify host genetic polymorphisms that are associated with susceptibility to agents of infectious diarrhea. Emphasizing infections due to Enterotoxigenic *E. coli* and *Cryptosporidium*.

Co-Investigator

OPT-099-001 DuPont (PI) 02/15/2006 – 10/31/2006  
 Advanced Biologics \$2,149,388  
 “A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy of Prulifloxacin Versus Placebo In The Treatment of Acute Bacterial Gastroenteritis In Adult Travelers; Protocol OPT-099-001;Phase 3”  
 The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.

Co-Investigator

RFID 3005 DuPont (PI) 03/01/2006 – 08/31/2006  
 Salix Pharmaceuticals, Inc. \$212,078.00

“A Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety of Rifaximin For the Prevention of Travelers’ Diarrhea For Subjects Traveling To Thailand From Switzerland”

The primary objective of this study is to assess the efficacy and safety of an 8- to 15-day course of rifaximin 600mg taken once daily as compared with placebo when taken by healthy subjects to prevent travelers’ diarrhea due to all causes.

Co-Investigator

ELT206 DuPont (PI) 06/01/2006 – 11/30/2006  
IOMAI, Corp. \$1,513,720

“A Phase II Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection with Enterotoxigenic *Escherichia coli* Occurring after Transcutaneous Immunization in the Field Setting”

The primary objective of this study is to evaluate the incidence of LT or LT/ST enterotoxigenic *E. coli* (ETEC) illness in a field setting and to evaluate the safety of LT patch recipients compared to placebo.

Co-Investigator

OPT-099-002 DuPont (PI) 10/01/2006 – 02/28/2007 10%  
Advanced Biologics \$296,400

“A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Prulifloxacin Versus Placebo In The Treatment Of Acute Gastroenteritis In Adult Travelers, Protocol OPT-099-002; Phase 3”

The purpose of this study is to investigate the safety and efficacy of prulifloxacin in the treatment of subjects with acute bacterial gastroenteritis.